全文获取类型
收费全文 | 299篇 |
免费 | 16篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 6篇 |
妇产科学 | 3篇 |
基础医学 | 36篇 |
口腔科学 | 13篇 |
临床医学 | 30篇 |
内科学 | 43篇 |
皮肤病学 | 2篇 |
神经病学 | 4篇 |
特种医学 | 45篇 |
外科学 | 28篇 |
综合类 | 70篇 |
预防医学 | 12篇 |
药学 | 5篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2021年 | 2篇 |
2019年 | 5篇 |
2018年 | 3篇 |
2017年 | 4篇 |
2016年 | 5篇 |
2015年 | 7篇 |
2014年 | 8篇 |
2013年 | 10篇 |
2012年 | 5篇 |
2011年 | 1篇 |
2010年 | 20篇 |
2009年 | 16篇 |
2008年 | 17篇 |
2007年 | 21篇 |
2006年 | 13篇 |
2005年 | 6篇 |
2004年 | 9篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 13篇 |
1998年 | 23篇 |
1997年 | 17篇 |
1996年 | 15篇 |
1995年 | 6篇 |
1994年 | 11篇 |
1993年 | 8篇 |
1992年 | 2篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 15篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 1篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1962年 | 1篇 |
1958年 | 3篇 |
1954年 | 2篇 |
1949年 | 1篇 |
排序方式: 共有321条查询结果,搜索用时 15 毫秒
71.
Acute leukemia in idiopathic sideroblastic anemia: response to combination chemotherapy 总被引:1,自引:0,他引:1
Three patients with idiopathic sideroblastic anemia of variable duration developed acute leukemia. In two the leukemia was morphologically and histochemically myeloblastic, in one lymphoblastic. With combination chemotherapy remission was achieved in all three. The remission inductions were complicated by long periods of bone marrow suppression and the duration of remissions was brief (3, 2 and 3 months). Survival after diagnosis was 13, 10 and 9 mo, respectively. The ring sideroblast abnormality persisted during the leukemic and remission phases and transfusion requirements remained unaltered in the two patients with transfusion dependent anemia throughout their courses. 相似文献
72.
AC Justice KA McGinnis M Skanderson CC Chang CL Gibert MB Goetz D Rimland MC Rodriguez‐Barradas KK Oursler ST Brown RS Braithwaite M May KE Covinsky MS Roberts SL Fultz KJ Bryant for the VACS Project Team 《HIV medicine》2010,11(2):143-151
Background
As those with HIV infection live longer, ‘non‐AIDS’ condition associated with immunodeficiency and chronic inflammation are more common. We ask whether ‘non‐HIV’ biomarkers improve differentiation of mortality risk among individuals initiating combination antiretroviral therapy (cART).Methods
Using Poisson models, we analysed data from the Veterans Aging Cohort Study (VACS) on HIV‐infected veterans initiating cART between 1 January 1997 and 1 August 2002. Measurements included: HIV biomarkers (CD4 cell count, HIV RNA and AIDS‐defining conditions); ‘non‐HIV’ biomarkers (haemoglobin, transaminases, platelets, creatinine, and hepatitis B and C serology); substance abuse or dependence (alcohol or drug); and age. Outcome was all cause mortality. We tested the discrimination (C statistics) of each biomarker group alone and in combination in development and validation data sets, over a range of survival intervals, and adjusting for missing data.Results
Of veterans initiating cART, 9784 (72%) had complete data. Of these, 2566 died. Subjects were middle‐aged (median age 45 years), mainly male (98%) and predominantly black (51%). HIV and ‘non‐HIV’ markers were associated with each other (P<0.0001) and discriminated mortality (C statistics 0.68–0.73); when combined, discrimination improved (P<0.0001). Discrimination for the VACS Index was greater for shorter survival intervals [30‐day C statistic 0.86, 95% confidence interval (CI) 0.80–0.91], but good for intervals of up to 8 years (C statistic 0.73, 95% CI 0.72–0.74). Results were robust to adjustment for missing data.Conclusions
When added to HIV biomarkers, ‘non‐HIV’ biomarkers improve differentiation of mortality. When evaluated over similar intervals, the VACS Index discriminates as well as other established indices. After further validation, the VACS Index may provide a useful, integrated risk assessment for management and research. 相似文献73.
Advances in the field of nanooncology 总被引:1,自引:0,他引:1
KK Jain 《BMC medicine》2010,8(1):83
Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most important chapter of
nanomedicine. Nanobiotechnology has refined and extended the limits of molecular diagnosis of cancer, for example, through
the use of gold nanoparticles and quantum dots. Nanobiotechnology has also improved the discovery of cancer biomarkers, one
such example being the sensitive detection of multiple protein biomarkers by nanobiosensors. Magnetic nanoparticles can capture
circulating tumor cells in the bloodstream followed by rapid photoacoustic detection. Nanoparticles enable targeted drug delivery
in cancer that increases efficacy and decreases adverse effects through reducing the dosage of anticancer drugs administered.
Nanoparticulate anticancer drugs can cross some of the biological barriers and achieve therapeutic concentrations in tumor
and spare the surrounding normal tissues from toxic effects. Nanoparticle constructs facilitate the delivery of various forms
of energy for noninvasive thermal destruction of surgically inaccessible malignant tumors. Nanoparticle-based optical imaging
of tumors as well as contrast agents to enhance detection of tumors by magnetic resonance imaging can be combined with delivery
of therapeutic agents for cancer. Monoclonal antibody nanoparticle complexes are under investigation for diagnosis as well
as targeted delivery of cancer therapy. Nanoparticle-based chemotherapeutic agents are already on the market, and several
are in clinical trials. Personalization of cancer therapies is based on a better understanding of the disease at the molecular
level, which is facilitated by nanobiotechnology. Nanobiotechnology will facilitate the combination of diagnostics with therapeutics,
which is an important feature of a personalized medicine approach to cancer. 相似文献
74.
P Yeni A LaMarca D Berger P Cimoch A Lazzarin P Salvato FM Smaill E Teofilo SJ Madison WG Nichols KK Adkison T Bonny J Millard D McCarty the EPIC study team 《HIV medicine》2009,10(2):116-124
Background
This phase IIb study explored the antiviral activity and safety of the investigational CC chemokine receptor 5 (CCR5) antagonist aplaviroc (APL) in antiretroviral‐naïve patients harbouring R5‐ or R5X4‐tropic virus.Methods
A total of 191 patients were randomized 2:2:2:1 to one of three APL dosing regimens or to lamivudine (3TC)/zidovudine (ZDV) twice daily (bid), each in combination with lopinavir/ritonavir (LPV/r) 400 mg/100 mg bid. Efficacy, safety and pharmacokinetic parameters were assessed.Results
This study was terminated prematurely because of APL‐associated idiosyncratic hepatotoxicity. A total of 141 patients initiated treatment early enough to have been able to complete 12 weeks on treatment [modified intent‐to‐treat (M‐ITT) population]; of these, 133 completed the 12‐week treatment phase. The proportion of subjects in the M‐ITT population with HIV‐1 RNA <400 copies/mL at week 12 was 50, 48, 54 and 75% in the APL 200 mg bid, APL 400 mg bid, APL 800 mg once a day (qd) and 3TC/ZDV arms, respectively. Similar responses were seen in the few subjects harbouring R5X4‐tropic virus (n=17). Common clinical adverse events (AEs) were diarrhoea, nausea, fatigue and headache. APL demonstrated nonlinear pharmacokinetics with high interpatient variability.Conclusions
While target plasma concentrations of APL were achieved, the antiviral activity of APL+LPV/r did not appear to be comparable to that of 3TC/ZDV+LPV/r. 相似文献75.
76.
77.
R Krempien MW Muenter PE Huber S Nill H Friess C Timke B Didinger P Buechler S Heeger KK Herfarth A Abdollahi MW Buchler J Debus 《BMC cancer》2005,5(1):1-11
Background
Pancreatic cancer is the fourth commonest cause of death from cancer in men and women. Advantages in surgical techniques, radiation therapy techniques, chemotherapeutic regimes, and different combined-modality approaches have yielded only a modest impact on the prognosis of patients with pancreatic cancer. Thus there is clearly a need for additional strategies. One approach involves using the identification of a number of molecular targets that may be responsible for the resistance of cancer cells to radiation or to other cytotoxic agents. As such, these molecular determinants may serve as targets for augmentation of the radiotherapy or chemotherapy response. Of these, the epidermal growth factor receptor (EGFR) has been a molecular target of considerable interest and investigation, and there has been a tremendous surge of interest in pursuing targeted therapy of cancers via inhibition of the EGFR.Methods/design
The PARC study is designed as an open, controlled, prospective, randomized phase II trial. Patients in study arm A will be treated with chemoradiation using intensity modulated radiation therapy (IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the patients receive gemcitabine infusions weekly over 4 weeks. Patients in study arm B will be treated with chemoradiation using intensity modulated radiation therapy (IMRT) combined with gemcitabine and simultaneous cetuximab infusions. After chemoradiation the patients receive gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks. A total of 66 patients with locally advanced adenocarcinoma of the pancreas will be enrolled. An interim analysis for patient safety reasons will be done one year after start of recruitment. Evaluation of the primary endpoint will be performed two years after the last patient's enrolment.Discussion
The primary objective of this study is to evaluate the feasibility and the toxicity profile of trimodal therapy in pancreatic adenocarcinoma with chemoradiation therapy with gemcitabine and intensity modulated radiation therapy (IMRT) and EGFR-targeted therapy using cetuximab and to compare between two different methods of cetuximab treatment schedules (concomitant versus concomitant and sequential cetuximab treatment). Secondary objectives are to determine the role and the mechanism of cetuximab in patient's chemoradiation regimen, the response rate, the potential of this combined modality treatment to concert locally advanced lesions to potentially resectable lesions, the time to progression interval and the quality of life. 相似文献78.
Gadolinium enhanced Magnetic Resonance Imaging (MRI) for the evaluation of the post operative lumbo-sacral spine is a sensitive and specific imaging technique. A need for establishing a specific protocol for Failed Back Surgery Syndrome (FBSS) for use in the service hospitals is highlighted for convenience of patient management and preservation of active manpower. The MR scan of 50 patients performed over a span of six months, who complained of persistent low backache even after surgery, were retrospectively analysed. The specificity of this series using MRI in indicating the exact cause of FBSS was clocked at only 30%. The conditions diagnosed were rectifiable. The balance of the patients who could not be offered any specific diagnosis towards the cause, were being managed conservatively / placed in low medical category for a considerable period. It was noted with concern that there was non prevalence of sequence like the fast spin echo with gadolinium enhancement as a routine.KEY WORDS: Gadolinium, Magnetic Resonance Imaging, Post-operative spine 相似文献
79.
Lau EMC; Cooper C; Fung H; Lam D; Tsang KK 《Journal of public health (Oxford, England)》1999,21(3):249-250
80.
4-S-(5″-烃基-4″-氨基-1″,2″,4″-三唑-3″-基)-4-去氧-4′-去甲基表鬼臼毒素衍生物的合成及抗肿瘤活性 总被引:1,自引:0,他引:1
许多有显著抗肿瘤活性的鬼臼毒素类化合物,其母核C-4侧链上往往连接有刚性较强的脂环或芳香环结构,而且侧链多含有一定数量的杂原子[1~3]。另外,三氮唑类化合物大都有广泛的生物活性,如抗菌[4~5]、抗病毒[6]、抗肿瘤[7]等,据此,我们设计并合成了8个三氮唑杂环取代的表鬼臼毒素衍生物,以期寻找活性高、毒副作用小的鬼臼毒素类药物,并进一步考察此类化合物的构效关系。 合成路线如图1所示,三氮唑3a~3h和4′-去甲基-表鬼臼毒2分别按文献[8,9]方法合成;我们选择三氟乙酸作为缩合剂,基于它不仅能催化缩合反应,而且能保护三唑上的氨基官能团,使其不能充当进攻基团;最后一步缩合反应显然经历了一个SN1历程,4′-去甲基-表鬼臼毒
的C-4位上很容易形成一个苄基型碳正离子,由于C-1位有庞大的芳环,加之,进攻的基团也较大,可以预料,这个反应有很强的立体选择性,使C-4β-构型成为主要产物,事实确实如此,在TLC上几乎看不到C-4α-构型的产物。 相似文献